4.8 Article

ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

期刊

MOLECULAR CELL
卷 81, 期 2, 页码 239-+

出版社

CELL PRESS
DOI: 10.1016/j.molcel.2020.11.006

关键词

-

资金

  1. NIH [R24DK106766, R01HL119479, R35GM134744]
  2. CPRIT [RR160029]
  3. Australian National Health and Medical Research Council [APP1164920]
  4. Australian Government Research Training Program
  5. St. Jude-sponsored CRC Consortium
  6. Cooley's Anemia Foundation

向作者/读者索取更多资源

ZNF410 is a pentadactyl DNA-binding protein that activates only one gene, CHD4, in human erythroid cells. Loss of ZNF410 leads to decreased CHD4 levels and derepression of fetal hemoglobin genes, revealing their sensitivity to reduced CHD4 levels. The specific binding sites near the CHD4 gene provide the specificity of ZNF410's transcriptional activation in erythroid cells.
Metazoan transcription factors typically regulate large numbers of genes. Here we identify via a CRISPR-Cas9 genetic screen ZNF410, a pentadactyl DNA-binding protein that in human erythroid cells directly activates only a single gene, the NuRD component CHD4. Specificity is conveyed by two highly evolutionarily conserved clusters of ZNF410 binding sites near the CHD4 gene with no counterparts elsewhere in the genome. Loss of ZNF410 in adult-type human erythroid cell culture systems and xenotransplantation settings diminishes CHD4 levels and derepresses the fetal hemoglobin genes. While previously known to be silenced by CHD4, the fetal globin genes are exposed here as among the most sensitive to reduced CHD4 levels.. In vitro DNA binding assays and crystallographic studies reveal the ZNF410-DNA binding mode. ZNF410 is a remarkably selective transcriptional activator in erythroid cells, and its perturbation might offer new opportunities for treatment of hemoglobinopathies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据